| Table 1. Description of included studies. | |||||||||
| Design | Randomization | Luteal Phase Support | ET day | ET catheter | Bed-Rest / no Bed-Rest | ||||
|---|---|---|---|---|---|---|---|---|---|
| (minutes) | Patients (n) | Age (years) | Number of Embryos Transferred | ||||||
| Sharif et al., 1998 | Retrospective | No | 100mg/day IM | 2, 3 | Embryon® | NA / 0 | 19697/ 1091 | NA | NA |
| Bar-Hava et al., 2005 | Prospective | No | NA | 3 | NA | 60 / 0 | 239/167 | 34.2 / 34.2 | 2.9 / 2.7 |
| Purcell et al., 2007 | RCT | Yes Numbered opaque envelope | IM (dose NA) | 2, 3, 5 | Wallace® | 30 / 0 | 82/82 | 36.9 / 36.8 | 3.3 / 3 |
| Gaikwad et al., 2013 | RCT | Yes Computer | 800mg/day PO | 3, 5, 6 | Wallace® | 10 / 0 | 120/ 20 | 41.2/ 40.9** | 2 / 2 |
ET: embryo transfer; n: sample size; RCT: randomized controlled study; NA: no information; IM: intramuscular; PO: orally
** The transfer was in ovum donation recipients